DIA analysis of Glioblastoma differentiated cells from different subtypes
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: 
Jean ARMENGAUD
LAB HEAD: Jean Armengaud
PROVIDER: PXD073353 | Pride | 2026-04-14
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E07369_MS24-037_MAM-5_3_12.raw | Raw | |||
| E07370_MS24-037_MAM-4_3_3.raw | Raw | |||
| E07371_MS24-037_MAM-7_2_17.raw | Raw | |||
| E07372_MS24-037_MAM-1_3_2.raw | Raw | |||
| E07373_MS24-037_MAM-7_1_16.raw | Raw |
Items per page: 5 1 - 5 of 25 |
Similar Datasets
Project description:Proteomic analysis of MAM-protein profiles in several GBM stem cell models with different subtypes, namely classical, proneural and mesenchymal.
2026-04-14 | PXD073390 | Pride
Project description:The mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) is the physical contact site between the ER and the mitochondria and plays a vital role in the regulation of calcium trafficking and bioenergetics. Previous studies suggest that disturbances in calcium trafficking and dysregulation of reactive oxygen species in the ER and mitochondria may contribute to the pathogenesis of diabetic retinopathy (DR). However, few studies have examined the impact of diabetes on the retinal MAM proteome profile. In the present study, we used Long Evans rats with streptozotocin-induced long-term Type 1 diabetes to identify key pathways and proteins in the retinal MAM that are potentially implicated in the pathogenesis of DR.
2022-10-15 | PXD033040 | Pride
Project description:We investigated the gene expression profiles of primary Human GBM cell lines. To represent the complexity of the GBM tissues, we uesd cell lines belonging to two different subtypes (HuTu10, proneural; HuTu13, Mesenchymal).
2020-10-02 | GSE133470 | GEO
Project description:Glioblastoma multiforme (GBM) is one of the most aggressive and therapy-resistant brain tumors prevalent in both adults and children. Despite extensive research to understand GBM pathology, it remains unclear how neural cells in the human brain interact with GBM cells to support their brain propagation and therapy resistance and whether GBM cells exert any influence on the properties of human neural cells. In this study, we co-culture human stem cell-derived subpallial telencephalic organoids with patient-derived proneural or mesenchymal GBM spheroids to investigate their reciprocal interactions. We show that both proneural and mesenchymal GBM spheroids readily fuse and propagate with human organoids, forming organoid-GBM chimeras, without the need for exogenous growth factors. GBM cells within the chimeras adapt by modulating gene expression profiles consistent with diminished proliferation, heightened hypoxia, increased angiogenesis, and proneural-to-mesenchymal transition in proneural GBM. Both proneural or mesenchymal GBMs also exert an impact on the properties of neural cells in the chimeras, leading to the suppression of neuronal genes and an upregulation expression of genes associated with hypoxia and angiogenesis. Collectively, this study identifies specific genes and molecular pathways that can be altered in GBM and neural cells by reciprocal interactions in a human developing brain-like environment for an increased understanding of GBM pathology and future therapy development.
2024-05-25 | GSE233532 | GEO
Project description:MAM (Microbial-Anti-Inflammatory Molecule) is a 14,5 kDa protein that is one of the best-known effector molecules with anti-inflammatory properties in Faecalibacterium duncaniae, a critical species in the human gut microbiota. Despite its importance, MAM function and molecular features remain poorly understood. Therefore, in this study, we sought to elucidate MAM's physiological importance. We investigated MAM localization using mass-spectrometry, immunogold labeling, and peptide secretion dynamics during bacterial growth. Bioinformatic analysis and microscopy further supported our understanding of MAM protein domain organization, interactions, and putative macromolecular assembly. Our results identified MAM as the most abundant protein in the cell envelope, and the second most abundant one in the overall proteome of F. duncaniae, with confirmed localization at the bacterial surface through immunogold labeling. Bioinformatics analysis highlights that MAM could comprise an N-terminal 21 residue leader peptide whose sequence contains all the motifs to be recognized and cleaved by a peptidase, followed by a 114 residue cargo peptide. Appropriately, in silico modeling suggests that the MAM leader peptide nicely accommodates the peptidase-domain-containing ABC transporter (PCAT) that is adjacent to MAM in the genome of F. duncaniae. After N-terminal excision, the cargo protein could be transported to the cell envelope via this PCAT, where it could assemble into a hexameric, pore-like structure, as revealed by AlphaFold3 modeling. Electron microscopy images of In situ F.duncaniae cells revealed a highly ordered lattice with repetitive units of hexamers. Moreover, an enriched fraction of MAM protein was obtained with in vitro LiCl extraction, exhibiting the same organizational pattern as the predicted hexameric organization. These findings provide the first comprehensive characterization and molecular export mechanisms of MAM as a key protein component of the F. duncaniae cell envelope, suggesting roles in cell structure, permeability, and communication with the host environment. It reveals a novel, lattice-like organization on the F. duncaniae cell envelope that may play a critical role in maintaining bacteria structure. This work introduces a novel discussion about the unique organization of the F.duncaniae cell envelope, having MAM as a key component for the bacteria, supporting the understanding of the unique biology of F. duncaniae and its potential as a next-generation probiotic or Live Biotherapeutics
2025-06-30 | PXD057939 | Pride
Project description:The gene expression profiles of two groups of triplicate human glioblastoma (GBM) xenografts grown in immunodeficient rats were compared. The first group of xenografts was derived from a patient biopsy with Epidermal Growth Factor Receptor (EGFR) amplification which grows highly invasive and is independent of angiogenesis. The second group was obtained by introducing a dominant-negative EGFR mutant into the tumor cells, leading to a progression of the tumors to an angiogenic phenotype associated with a transition from a proneural to a mesenchymal GBM molecular subtype.
2017-07-05 | E-MTAB-4898 | biostudies-arrayexpress
Project description:Glioblastoma (GBM) cells’ stemness-like features and lineage plasticity promote tumor progression. Here, we demonstrate that Clemastine, a drug for treating hay fever and allergy symptoms, effectively attenuated the stemness and suppressed the propagation of primary GBM cultures bearing PDGFRA amplification. We show that these effects of GBM cells were accompanied by altered gene expression profiling indicative of a more differentiated state of tumor cells, in resonating with Clemastine’s activity in promoting the differentiation of normal oligodendrocyte progenitors (OPCs) into mature oligodendrocyte. Functional assays for proteins that can be pharmacologically targeted by Clemastine, including histamine receptors, muscarinic receptors, and Emopamil binding protein (EBP), revealed the essential roles of these proteins in sustaining GBM cell propagation and suggested that Clemastine likely impairs tumor cells via targeting multiple pathways. Finally, we showed that a PDGFB-driven mouse glioma model, representing the proneural subtype GBMs, was similarly susceptible to Clemastine treatment. Collectively, these results identify pathways that are essential for maintaining the proneural progenitor features of GBMs, and suggest that non-oncology, low toxicity drugs with OPC differentiation promoting effects, such as Clemastine, can be exploited for targeting GBM cell’s progenitor property.
2023-10-04 | GSE186319 | GEO
Project description:Diabetic cardiomyopathy (DCM) strongly leads to heart failure, notably with preserved ejection fraction (HFpEF). The involvement of mitochondria-associated reticular membranes (MAM) in T2D-related metabolic disorders starts to be demonstrated. In order to characterize the cardiac phenotype of an obesogenic type II diabetic mouse model (leptin-deficient ob/ob), we compared the proteome of its MAMs with those from WT mice.
2025-06-16 | PXD054672 | Pride
Project description:Glioblastoma (GBM) cells’ stemness-like features and lineage plasticity promote tumor progression. Here, we demonstrate that Clemastine, a drug for treating hay fever and allergy symptoms, effectively attenuated the stemness and suppressed the propagation of primary GBM cultures bearing PDGFRA amplification. We show that these effects of GBM cells were accompanied by altered gene expression profiling indicative of a more differentiated state of tumor cells, in resonating with Clemastine’s activity in promoting the differentiation of normal oligodendrocyte progenitors (OPCs) into mature oligodendrocyte. Functional assays for proteins that can be pharmacologically targeted by Clemastine, including histamine receptors, muscarinic receptors, and Emopamil binding protein (EBP), revealed the essential roles of these proteins in sustaining GBM cell propagation and suggested that Clemastine likely impairs tumor cells via targeting multiple pathways. Finally, we showed that a PDGFB-driven mouse glioma model, representing the proneural subtype GBMs, was similarly susceptible to Clemastine treatment. Collectively, these results identify pathways that are essential for maintaining the proneural progenitor features of GBMs, and suggest that non-oncology, low toxicity drugs with OPC differentiation promoting effects, such as Clemastine, can be exploited for targeting GBM cell’s progenitor property.
2023-10-04 | GSE186392 | GEO
Project description:SUMMARY Despite numerous genome-wide association studies involving glioblastoma (GBM), few therapeutic targets have been identified for this disease. Using patient derived glioma sphere cultures (GSCs), we have found that a subset of the proneural (PN) GSCs undergo transition to a mesenchymal (MES) state in a TNFa/NFkB dependent manner with an associated enrichment of CD44 sub-populations and radio-resistant phenotypes. To the contrary, MES GSCs exhibit constitutive NFkB activation, CD44 enrichment and radio-resistance. Patients whose tumors exhibit a higher MES metagene, increased expression of CD44, or activated NFkB were associated with poor radiation response and shorter survival. Our results indicate that NFkB activation mediated MES differentiation and radiation resistance presents an attractive therapeutic target for GBM. SIGNIFICANCE In this study, we show plasticity between the proneural (PN) and mesenchymal (MES) transcriptome signatures observed in glioblastoma (GBM). Specifically, we show that PN glioma sphere cultures (GSCs) can be induced to a MES state with an associated enrichment of CD44 expressing cells and a gain of radio-resistance, which we implicate as NFkB- dependent. Newly diagnosed GBM samples show a direct correlation between radiation response, higher MES metagene, CD44 expression, and NFkB activation. This correlation is also observed in the subset of GBM samples that do not exhibit IDH1 mutation, a favorable prognostic marker. Our results uncover a previously unknown link between subtype plasticity that is regulated by NFkB. Inhibition of NFkB activation can directly impact radio-resistance and presents an attractive therapeutic target for GBM. 4 treatments
2013-08-15 | E-GEOD-49162 | biostudies-arrayexpress